In Vitro and In Vivo biodistribution of ZRS1, a stabilized type I N-Acetoxymethyl carbamate-containing combi-molecule

Drug Metabolism Letters

Volumn 5, Issue 2, 2011, Pages 141-149

  Golabi, Nahid ^a   Rachid, Zakaria ^a   Qiu, Qiyu ^a   Huang, Ying ^a   Jean Claude, Bertrand J ^a  

^a ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

Combi molecule; DNA damage; EGFR inhibition; In vivo; Multilayer aggregates

Indexed keywords

BJ 2000; DIAZONIUM COMPOUND; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FD 105; FD 105AC; PRODRUG; RB 107; TRIAZENE DERIVATIVE; UNCLASSIFIED DRUG; ZRS 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; DRUG DEGRADATION; DRUG DESIGN; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG POTENCY; DRUG STABILITY; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER;

ANIMALS; CARBAMATES; CELL AGGREGATION; CELL LINE, TUMOR; FEMALE; HUMANS; MALE; MICE; MICE, INBRED BALB C; PRODRUGS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TISSUE DISTRIBUTION; TRIAZENES;

EID: 79954556455     PISSN: 18723128     EISSN: None     Source Type: Journal    
DOI: 10.2174/187231211795305212     Document Type: Article

References (31)

1. Bei, R.; Marzocchella, L.; Turriziani, M., The use of temozolomide for the treatment of malignant tumors: clinical evidence and molecular mechanisms of action. Recent Pat. Anticancer Drug Discov., 2010, 5 (3), 172-187.
2. Newlands, E.S.; Stevens, M.F.; Wedge, S.R.; Wheelhouse, R.T.; Brock, C., Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev., 1997, 23 (1), 35-61.
3. Quirt, I.; Verma, S.; Petrella, T.; Bak, K.; Charette, M., Temozolomide for the treatment of metastatic melanoma: a systematic review. Oncologist, 2007, 12 (9), 1114-1123.
4. Matheson, S.L.; McNamee, J.P.; Jean-Claude, B.J., Differential responses of EGFR-/AGT-expressing cells to the "combi-triazene" SMA41. Cancer Chemoth. Pharm., 2003, 51 (1), 11-20.
5. Griffin, R.J.; Arris, C.E.; Bleasdale, C.; Boyle, F.T.; Calvert, A.H.; Curtin, N.J.; Dalby, C.; Kanugula, S.; Lembicz, N.K.; Newell, D.R.; Pegg, A.E.; Golding, B.T., Resistance-modifying agents. 8. Inhibition of O(6)-alkylguanine-DNA alkyltransferase by O(6)- alkenyl-, O(6)-cycloalkenyl-, and O(6)-(2-oxoalkyl)guanines and potentiation of temozolomide cytotoxicity in vitro by O(6)-(1- cyclopentenylmethyl)guanine. J. Med. Chem., 2000, 43 (22), 4071-4083.
6. Kokkinakis, D.M.; Bocangel, D.B.; Schold, S.C.; Moschel, R.C.; Pegg, A.E., Thresholds of O6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide. Clin. Cancer Res., 2001, 7 (2), 421-428.
7. Matheson, S.L.; McNamee, J.; Jean-Claude, B.J., Design of a chimeric 3-methyl-1,2,3-triazene with mixed receptor tyrosine kinase and DNA damaging properties: a novel tumor targeting strategy. J. Pharmacol. Exp. Ther., 2001, 296 (3), 832-840.
8. Bertrand, J.-C.; Dudouit, F.; Matheson, S. Combi-molecules having signal transduction inhibitory properties and DNA damaging properties, (McGill University, Can.). Application: WO, 2002, pp.91.
9. [MacPhee, M.; Rachid, Z.; Todorova, M.; Qiu, Q.; Belinsky, G.; Jean-Claude, B., Characterization of the potency of epidermal growth factor (EGFR)-DNA targeting combi-molecules containing a hydrolabile carbamate at the 3-position of the triazene chain. Invest. New Drugs, 2010, 1-13.
10. Rachid, Z.; Brahimi, F.; Qiu, Q.; Williams, C.; Hartley, J.M.; Hartley, J.A.; Jean-Claude, B.J., Novel Nitrogen Mustard-Armed Combi-Molecules for the Selective Targeting of Epidermal Growth Factor Receptor Overexperessing Solid Tumors: Discovery of an Unusual Structure-Activity Relationship. J. Med. Chem., 2007, 50 (11), 2605-2608.
11. Rachid, Z.; Brahimi, F.; Domarkas, J.; Jean-Claude, B.J., Synthesis of half-mustard combi-molecules with fluorescence properties: correlation with EGFR status. Bioorg. Med. Chem. Lett., 2005, 15 (4), 1135-1138.
12. Banerjee, R.; Huang, Y.; McNamee, J.P.; Todorova, M.; Jean-Claude, B.J., The combi-targeting concept: selective targeting of the epidermal growth factor receptor- and Her2-expressing cancer cells by the complex combi-molecule RB24. J. Pharmacol. Exp. Ther., 2010, 334 (1), 9-20.
13. Brahimi, F.; Matheson, S.L.; Dudouit, F.; McNamee, J.P.; Tari, A.M.; Jean-Claude, B.J., Inhibition of epidermal growth factor receptor-mediated signaling by "Combi-Triazene" BJ2000, a new probe for Combi-Targeting postulates. J. Pharmacol. Exp. Ther., 2002, 303 (1), 238-246.
14. Domarkas, J.; Dudouit, F.; Williams, C.; Qiyu, Q.; Banerjee, R.; Brahimi, F.; Jean-Claude, B.J., The combi-targeting concept: synthesis of stable nitrosoureas designed to inhibit the epidermal growth factor receptor (EGFR). J. Med. Chem.,2006, 49 (12), 3544-3552.
15. Qiu, Q.; Domarkas, J.; Banerjee, R.; Merayo, N.; Brahimi, F.; McNamee, J.P.; Gibbs, B.F.; Jean-Claude, B.J., The Combi- Targeting Concept: In vitro and In vivo Fragmentation of a Stable Combi-Nitrosourea Engineered to Interact with the Epidermal Growth Factor Receptor while Remaining DNA Reactive. Clin. Cancer Res., 2007, 13 (1), 331-340.
16. Rachid, Z.; Katsoulas, A.; Williams, C.; Larroque, A.L.; McNamee, J.; Jean-Claude, B.J., Optimization of novel combimolecules: identification of balanced and mixed bcr-abl/DNA targeting properties. Bioorg. Med. Chem. Lett., 2007, 17 (15), 4248-4253.
17. Rachid, Z.; MacPhee, M.; Williams, C.; Todorova, M.; Jean-Claude, B.J., Design and synthesis of new stabilized combitriazenes for targeting solid tumors expressing the epidermal growth factor receptor (EGFR) or its closest homologue HER2. Bioorg. Med. Chem. Lett. 2009, 19 (18), 5505-5509.
18. Qiu, Q.; Domarkas, J.; Banerjee, R.; Katsoulas, A.; McNamee, J.P.; Jean-Claude, B.J., Type II combi-molecules: design and binary targeting properties of the novel triazolinium-containing molecules JDD36 and JDE05. Anti-Cancer Drugs, 2007, 18 (2), 171-177.
19. Banerjee, R.; Rachid, Z.; McNamee, J.; Jean-Claude, B.J., Synthesis of a prodrug designed to release multiple inhibitors of the epidermal growth factor receptor tyrosine kinase and an alkylating agent: a novel tumor targeting concept. J. Med. Chem., 2003, 46 (25), 5546-5551.
20. Qiu, Q.; Larroque, A.L.; Gibbs, B.; Fang, Y.; Lakhrissi, Y.; Soucy, J.P.; Mzengeza, S.; Rachid, Z.; Jean-Claude, B.J., Molecular analysis of the in vivo metabolism and biodistribution of metabolically and non-metabolically activated combi-molecules of the triazene class. Drug Metab. Lett., 2009, 3 (1), 1-9.
21. Banerjee, R.; Rachid, Z.; Qiu, Q.; McNamee, J.P.; Tari, A.M.; Jean-Claude, B.J., Sustained antiproliferative mechanisms by RB24, a targeted precursor of multiple inhibitors of epidermal growth factor receptor and a DNA alkylating agent in the A431 epidermal carcinoma of the vulva cell line. Br. J. Cancer, 2004, 91 (6), 1066-1073.
22. Morazzani, M.; de Carvalho, D.D.; Kovacic, H.; Smida-Rezgui, S.; Briand, C.; Penel, C., Monolayer versus aggregate balance in survival process for EGF-induced apoptosis in A431 carcinoma cells: Implication of ROS-P38 MAPK-integrin alpha2beta1 pathway. Int. J. Cancer, 2004, 110 (6), 788-799.
23. Padron, J.M.; van der Wilt, C.L.; Smid, K.; Smitskamp-Wilms, E.; Backus, H.H.; Pizao, P.E.; Giaccone, G.; Peters, G.J., The multilayered postconfluent cell culture as a model for drug screening. Crit. Rev. Oncol. Hematol., 2000, 36 (2-3), 141-157.
24. Puiffe, M.L.; Le Page, C.; Filali-Mouhim, A.; Zietarska, M.; Ouellet, V.; Tonin, P.N.; Chevrette, M.; Provencher, D.M.; Mes-Masson, A.M., Characterization of ovarian cancer ascites on cell invasion, proliferation, spheroid formation, and gene expression in an in vitro model of epithelial ovarian cancer. Neoplasia, 2007, 9 (10), 820-829.
25. Vaughan, K.; Tang, Y.; Llanos, G.; Horton, J.K.; Simmonds, R.J.; Hickman, J.A.; Stevens, M.F., Studies of the mode of action of antitumor triazenes and triazines. 6. 1-Aryl-3-(hydroxymethyl)-3- methyltriazenes: synthesis, chemistry, and antitumor properties. J. Med. Chem., 1984, 27 (3), 357-363.
26. Reid, J.M.; Kuffel, M.J.; Miller, J.K.; Rios, R.; Ames, M.M., Metabolic activation of dacarbazine by human cytochromes P450: the role of CYP1A1, CYP1A2, and CYP2E1. Clin.Cancer Res., 1999, 5 (8), 2192-2197.
27. Banerjee, R.; Huang, Y.; Qiu, Q.; James, J.; Belinsky, G.; Jean-Claude, B.J., The combi-targeting concept: mechanism of action of the pleiotropic combi-molecule RB24 and discovery of a novel cell signaling-based combination principle Cellular Signaling, 2011, 23: 630-640
28. Perry Mde, J.; Carvalho, E.; Rosa, E.; Iley, J., Towards an efficient prodrug of the alkylating metabolite monomethyltriazene: synthesis and stability of N-acylamino acid derivatives of triazenes. Eur.J. Med. Chem., 2009, 44 (3), 1049-1056.
29. Huang, Y.; Rachid, Z.; Jean-Claude, B.J., O6-methylguanine DNA methyltransferase (MGMT) is a molecular determinant for potency of the DNA-epidermal growth factor receptor (EGFR) targeting combimolecule ZRS1 Molecular Cancer Research, 2011, 9, 320-331.
30. Carvalho, E.; Francisco, A.P.; Iley, J.; Rosa, E., Triazene drug metabolites. Part 17: Synthesis and plasma hydrolysis of acyloxymethyl carbamate derivatives of antitumour triazenes. Bioorg. Med. Chem., 2000, 8 (7), 1719-1725.
31. Merayo, N.; Rachid, Z.; Qiu, Q.; Brahimi, F.; Jean-Claude, B.J., The combi-targeting concept: evidence for the formation of a novel inhibitor in vivo. Anti-Cancer Drugs, 2006, 17 (2), 165-171.